Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 24, 2024

p53 (7F5) Rabbit mAb

RRID:AB_10695803
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 2527, RRID:AB_10695803)

Antibody Information

URL: http://antibodyregistry.org/AB_10695803

Proper Citation: (Cell Signaling Technology Cat# 2527, RRID:AB_10695803)

Target Antigen: p53 (7F5) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC, F, ChIP. Consolidation on 10/2018: AB_10695803, AB_331211.

Antibody Name: p53 (7F5) Rabbit mAb

Description: This monoclonal targets p53 (7F5) Rabbit mAb

Target Organism: h, mk, human

Antibody ID: AB_10695803

Vendor: Cell Signaling Technology

Catalog Number: 2527

Ratings and Alerts

No rating or validation information has been found for p53 (7F5) Rabbit mAb.

No alerts have been found for p53 (7F5) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Li N, et al. (2024) Bi-allelic variants in CEP295 cause Seckel-like syndrome presenting with primary microcephaly, developmental delay, intellectual disability, short stature, craniofacial and digital abnormalities. EBioMedicine, 99, 104940.

Herrera JL, et al. (2024) Akt3 activation by R-Ras in an endothelial cell enforces quiescence and barrier stability of neighboring endothelial cells via Jagged1. Cell reports, 43(3), 113837.

Chung CL, et al. (2024) Fluoroquinolones upregulate insulin-like growth factor-binding protein 3, inhibit cell growth and insulin-like growth factor signaling. European journal of pharmacology, 969, 176421.

Fondevila MF, et al. (2024) p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway. Cell reports. Medicine, 5(2), 101401.

Abdelrahim M, et al. (2024) Light-mediated intracellular polymerization. Nature protocols.

He Y, et al. (2023) Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation. Cell reports, 42(2), 112033.

Wang X, et al. (2023) Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell reports, 42(1), 111972.

Hong Y, et al. (2023) Elabela inhibits TRAF1/NF-?B induced oxidative DNA damage to promote diabetic foot ulcer wound healing. iScience, 26(9), 107601.

Fischer JR, et al. (2023) Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. Cell reports. Medicine, 4(3), 100977.

Ikliptikawati DK, et al. (2023) Nuclear transport surveillance of p53 by nuclear pores in glioblastoma. Cell reports, 42(8), 112882.

Park SM, et al. (2023) Dual IKZF2 and CK1? degrader targets acute myeloid leukemia cells. Cancer cell, 41(4), 726.

Bhagwani AR, et al. (2023) A p53-TLR3 axis ameliorates pulmonary hypertension by inducing BMPR2 via IRF3. iScience, 26(2), 105935.

Kudo KI, et al. (2022) ?Np63? transcriptionally represses p53 target genes involved in the radiation-induced DNA damage response : ?Np63? may cause genomic instability in epithelial stem cells. Radiation oncology (London, England), 17(1), 183.

Coutinho DF, et al. (2022) Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. Med (New York, N.Y.), 3(11), 774.

Li H, et al. (2022) Poroptosis: A form of cell death depending on plasma membrane nanopores formation. iScience, 25(6), 104481.

Maor-Nof M, et al. (2021) p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). Cell, 184(3), 689.

Yu VZ, et al. (2021) Gain-of-function hot spot mutant p53R248Q regulation of integrin/FAK/ERK signaling in esophageal squamous cell carcinoma. Translational oncology, 14(1), 100982.

Fischer N, et al. (2021) A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy. Investigational new drugs, 39(4), 914.

Fankhauser M, et al. (2019) Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 160(11), 2600.

Lambert JP, et al. (2019) Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains. Molecular cell, 73(3), 621.